Kelun-Biotech’s Sac-TMT shows breakthrough results in first-line lung cancer trial
Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
Call it a ray of hope for those enduring the pain of knee osteoarthritis -- the most common form of arthritis, affecting over 300 million people worldwide
It's a development that marks a major step forward for patients struggling with moderate-to-severe chronic spontaneous urticaria
Pfizer and Valneva have been collaborating on VLA15’s development and commercialization since April 2020
The trial tested six injectable doses and three oral doses over as long as 36 weeks
Elevidys came under scrutiny in June when the FDA disclosed two fatal cases in non-ambulatory boys who developed dangerously high liver enzyme levels
Millions of stroke survivors across the world may soon have a new defense
The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in invasive disease-free survival
FDA closes inspection at Zydus' oncology injectable manufacturing facility in SEZ1, Ahmedabad with 2 observations
Subscribe To Our Newsletter & Stay Updated